Jefferies Reiterates Buy Rating on Sarepta Therapeutics (SRPT); cites as potential "recovery story"
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 18.62 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.62 | 52 Week High | $63.73 | |||
| Open | $18.62 | 52 Week Low | $8.00 | |||
| Day High | $18.62 | P/E | N/A | |||
| Day Low | $18.62 | EPS | $-5.69 | |||
| Volume | 4,008 | |||||
